Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination with Fulvestrant in Postmenopausal Patients with HR2-positive, HER2-negative Breast Cancer That Had Progressed During or After Prior Endocrine Therapy

Dovitinib in combination with fulvestrant showed promising clinical activity in a FGF pathway-amplified subgroup. However, the data reported from this study should be interpreted with caution, given that fewer progression-free survival events occurred in the FGF pathway-amplified patients than was expected.

 Breast Cancer Res

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.